FARMINGTON HILLS—Ocuphire Pharma Inc., a clinical-stage pharmaceutical company developing therapies to treat patients with a variety of ophthalmic disorders, announced that it has closed on over $5 million of financing.

Investors include Jackson-based RBI Opportunities Fund, Douglas, Mich.-based Belle Capital Fund, Grand Rapids-based Grand Angels Fund, Farmington Hills-based First Capital Fund, Ann Arbor-based Michigan Angel Fund, Kalamazoo-based Biosciences Research and Commercialization Center, Ann Arbor Angels, Detroit-based Woodward Angels, Kalamazoo Angels, Midland-based BlueWater Angels, and other individual and institutional investors.

Company officials said proceeds of the offering will be used to fund multiple clinical trials of its lead drug candidate, Nyxol.

To read more, click on